Amgen Inc. (NASDAQ:AMGN) – Research analysts at Jefferies Group boosted their FY2017 EPS estimates for Amgen in a research report issued on Tuesday. Jefferies Group analyst M. Yee now expects that the medical research company will earn $12.57 per share for the year, up from their previous estimate of $12.49. Jefferies Group has a “Buy” rating and a $195.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. Vetr cut Amgen from a “strong-buy” rating to a “buy” rating and set a $178.82 price target for the company. in a research report on Monday, April 3rd. Mizuho reiterated a “buy” rating and set a $195.00 price target on shares of Amgen in a research report on Monday, April 3rd. Oppenheimer Holdings, Inc. set a $189.00 price target on Amgen and gave the company a “buy” rating in a research report on Tuesday, May 9th. Cowen and Company reiterated a “buy” rating and set a $209.00 price target on shares of Amgen in a research report on Thursday, April 27th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $198.00 price target (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $186.81.

COPYRIGHT VIOLATION WARNING: “Jefferies Group Analysts Boost Earnings Estimates for Amgen Inc. (AMGN)” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/07/27/jefferies-group-analysts-boost-earnings-estimates-for-amgen-inc-amgn.html.

Amgen (NASDAQ AMGN) traded down 1.98% during mid-day trading on Thursday, reaching $172.40. 1,139,831 shares of the company traded hands. The firm has a market capitalization of $126.78 billion, a P/E ratio of 16.38 and a beta of 1.36. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The company’s 50 day moving average price is $171.84 and its 200 day moving average price is $166.15.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 30.17%. The company had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the stock. Camelot Portfolios LLC purchased a new stake in Amgen during the first quarter valued at about $1,429,000. Private Asset Management Inc. increased its stake in Amgen by 117.8% in the first quarter. Private Asset Management Inc. now owns 3,591 shares of the medical research company’s stock valued at $589,000 after buying an additional 1,942 shares in the last quarter. Cadence Bank NA increased its stake in Amgen by 6.2% in the first quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock valued at $554,000 after buying an additional 197 shares in the last quarter. Stillwater Capital Advisors LLC purchased a new stake in Amgen during the first quarter valued at about $202,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in Amgen during the fourth quarter valued at about $275,209,000. Hedge funds and other institutional investors own 78.87% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.